.Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CJ02_Lemborexant.Lemborexant .Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CJ02_Lemborexant.Lemborexant| name: | Lemborexant |
| ATC code: | N05CJ02 | route: | oral |
| n-compartments | 2 |
Lemborexant is a dual orexin receptor antagonist used for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. It is an orally active, prescription hypnotic agent approved for adults by regulatory agencies such as the FDA.
Pharmacokinetic parameters were reported in healthy adult subjects (aged 18–88), both male and female, primarily following oral administration in clinical and Phase I studies.
Lalovic, B, et al., & Hussein, Z (2020). Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder. Journal of clinical pharmacology 60(12) 1642–1654. DOI:10.1002/jcph.1683 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32666570